Reich K, Armstrong AW, Langley RG, et al. – In this phase 3, multicenter, double-blind, randomized, comparator-controlled trial that was conducted at 142 outpatient clinical sites in 9 countries (including the United States), researchers demonstrated the advantage of clinical response at week 48 for guselkumab vs secukinumab. The study sample consisted of 1,048 adults with moderate-to-severe plaque-type psoriasis. Participants were randomized to receive either guselkumab (100 mg at weeks 0 and 4, then every 8 weeks) or secukinumab (300 mg at weeks 0, 1, 2, 3, and 4, and then every 4 weeks). In the guselkumab group vs the secukinumab group, the proportion of patients with a PASI 90 response at week 48 was larger. Although non-inferiority was established for the first principal secondary endpoint, superiority was not. Consequently, for subsequent major secondary endpoints, formal statistical testing was not performed. Among the two treatments, proportions of patients with adverse events, infections, and serious adverse events were comparable and, in general, safety conclusions were constant with registrational trial observations. Hence, for treating moderate-to-severe psoriasis, better long-term efficiency based on PASI 90 at week 48 was exhibited by guselkumab when compared with secukinumab.